Carlos Zevallos, DO
Rheumatology · Akron, OHNPI 1619931433
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,878 of the $15,640 with a category attached, or 88.7%. It is spread thinly across 37 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations.
Across 847 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Johnson & Johnson$3K
- AbbVie$2K
- Pfizer$1K
- UCB, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$990
- plus $4K from 31 others
What the payments were for
- Consulting fees$1,62010%
- Travel & lodging$540%
- Food & beverage$13,87889%
- Education$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 182 | $3,247 |
| Johnson & Johnson | 69 | $2,695 |
| AbbVie | 158 | $2,105 |
| Pfizer | 87 | $1,137 |
| UCB, Inc. | 38 | $1,012 |
| E.r. Squibb & Sons, L.L.C. | 68 | $990 |
| Genentech USA, Inc. | 34 | $597 |
| Novartis | 37 | $565 |
| Lilly USA, LLC | 30 | $536 |
| GSK | 27 | $478 |
| Radius Health, Inc. | 24 | $385 |
| Aurinia Pharma U.S., Inc. | 9 | $300 |
| AstraZeneca(2 entities) | 15 | $283 |
| Regeneron Healthcare Solutions, Inc. | 8 | $179 |
| ANI Pharmaceuticals, Inc. | 3 | $156 |
| Boehringer Ingelheim | 7 | $124 |
| Organon | 5 | $121 |
| Sandoz | 7 | $110 |
| Mallinckrodt Enterprises LLC | 6 | $101 |
| Bristol Myers Squibb | 5 | $85 |
| Mallinckrodt Hospital Products Inc. | 5 | $64 |
| Pacira Therapeutics, Inc. | 3 | $54 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Hikma Pharmaceuticals USA | 3 | $39 |
| Merck | 2 | $27 |
| Sebela Pharmaceuticals Inc. | 2 | $24 |
| Biocon Biologics Inc | 1 | $24 |
| Mylan Institutional Inc. | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Octapharma USA, Inc. | 1 | $19 |
| Medexus Pharma, Inc. | 1 | $18 |
| Sanofi | 1 | $16 |
| Fresenius Kabi USA, LLC | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Fidia Pharma USA Inc. | 1 | $12 |
| Ferring Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,640 in reported general payments places this provider in the 85th percentile of 255 rheumatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 70 | $648,293 |
| Humira(Cf) PenAdalimumab | 32 | $258,761 |
| EnbrelEtanercept | 28 | $245,802 |
| OrenciaAbatacept | 20 | $123,599 |
| Xeljanz XrTofacitinib Citrate | 20 | $120,071 |
| Teriparatide | 18 | $62,440 |
| ForteoTeriparatide | 13 | $60,632 |
| OtezlaApremilast | 11 | $55,244 |
| ProliaDenosumab | 23 | $40,654 |
| Hydroxychloroquine Sulfate | 942 | $32,720 |
| Leflunomide | 192 | $12,715 |
| Celecoxib | 228 | $12,586 |
| MethotrexateMethotrexate Sodium | 422 | $10,129 |
| Sulfasalazine DrSulfasalazine | 159 | $7,267 |
| Prednisone | 700 | $6,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla, Prolia | $3,247 | $341,70062 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $990 | $123,59920 claims |
| Lilly USA, LLCForteo | $536 | $60,63213 claims |
| SandozLansoprazole | $110 | $48611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 rheumatology providers in Ohio.
Other rheumatology in Akron
- David BachaAkron$179K
- Margaret PullinAkron$25K
- Megan BielawskiAkron$13K
- William WojnoAkron$9K
- Leonard CalabreseCleveland$1.9M
- Gregory DelorenzoCincinnati$1.3M
- Alexa MearaColumbus$426K
- Chad DealCleveland$375K
- David MandelMayfield Village$352K
- Muhammad KhanCleveland$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.